Income statement
USD
Annual
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -12M | -28M | -10M | -3M | -686K |
| EBITDA | -12M | -26M | -10M | -3M | -686K |
| Net Income | -12M | -28M | -12M | -3M | -686K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0004
+0.00% today
1Y Change
+33.33%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 250 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Scopus BioPharma Inc. (SCPS) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 33.3% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +65.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +65.8%, free cash flow +28.9% with operating margin 0.0% and ROIC 164.4%. Stock Foundry combines SCPS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SCPS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SCPS Max Drawdown
-70.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SCPS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$686.0K
+74.5% YoY
Free Cash Flow
-$747.3K
+64.8% YoY
Revenue Growth
+0.0%
EPS Growth
+65.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -12M | -28M | -10M | -3M | -686K |
| EBITDA | -12M | -26M | -10M | -3M | -686K |
| Net Income | -12M | -28M | -12M | -3M | -686K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 125K | 8M | 2M | 37K | 2K |
| Total Assets | 392K | 8M | 2M | 772K | 133K |
| Total Liabilities | 7M | 4M | 4M | 855K | 138K |
| Shareholder Equity | -7M | 4M | -2M | -83K | -5K |
| Total Debt | 0 | 0 | 2M | 0 | 0 |
| Net Debt | -125K | -8M | 452K | -37K | -2K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
747K
+64.8% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
747K
+64.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
911.7%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.